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ABSTRACT: It is urgent to find new antibiotic classes with activity against multidrug-
resistant (MDR) Gram-negative pathogens as the pipeline of antibiotics is essentially
empty. Modified pyrrolobenzodiazepines with a C8-linked aliphatic heterocycle provide a
new class of broad-spectrum antibacterial agents with activity against MDR Gram-negative
bacteria, including WHO priority pathogens. The structure−activity relationship
established that the third ring was particularly important for Gram-negative activity.
Minimum inhibitory concentrations for the lead compounds ranged from 0.125 to 2 mg/L
for MDR Gram-negative, excluding Pseudomonas aeruginosa, and between 0.03 and 1 mg/L
for MDR Gram-positive species. The lead compounds were rapidly bactericidal with >5 log
reduction in viable count within 4 h for Acinetobacter baumannii and Klebsiella pneumoniae.
The lead compound inhibited DNA gyrase in gel-based assays, with an IC50 of 3.16 ± 1.36
mg/L. This study provides a new chemical scaffold for developing novel broad-spectrum
antibiotics which can help replenish the pipeline of antibiotics.
■ INTRODUCTION
The fight against bacterial infections is rapidly being lost as
microbes develop multiple mechanisms to evade antibiotics.
Antimicrobial resistance is one of the most significant health
concerns worldwide. It is estimated that 25,000 people die
each year in Europe and 23,000 people die each year in the
United States because of resistant bacterial infections, with
more than 2 million infections caused by drug-resistant
bacteria.1 These values are expected to reach 10 million
deaths globally by 2050, overtaking cancer and heart disease as
the principal cause of death if no effective measures can be
developed.2 Of particular concern is the rapid emergence of
multidrug-resistant (MDR) Gram-negative pathogens, defined
as having resistance to at least three frontline antibiotic classes,
and there are increasing reports of essentially pan-drug-
resistant (PDR) isolates in the clinic. In the last 30 years, no
major classes of broad-spectrum antibiotics have been
introduced to the market, and recently, approved agents such
as linezolid (2000), daptomycin (2003), and retapamutilin
(2007) are active only against Gram-positive pathogens.3 This
makes it imperative that we discover new antibacterial drugs
with a broad spectrum of activity or specificity for Gram-
negative species, in order to help solve the crisis and provide
new treatment options for MDR and PDR strains.
Pyrrolobenzodiazepines (PBDs) are naturally occurring
molecules produced by Streptomyces bacteria whose family
members include anthramycin and tomaymycin.4,5 PBDs have
a soft N10−C11 imine electrophile that can covalently bond to
guanine bases.6 They have been extensively studied as
anticancer agents7−11 and, more recently, a large number of
PBDs are being clinically evaluated as payloads for antibody
drug conjugates (ADCs) demonstrating the broad therapeutic
utility of this chemical class.12,13 We recently described a series
of C8-linked PBD monomers that showed activity against
Gram-positive MDR strains,14,15 which were able to inhibit
Staphylococcus gyrase in a biochemical assay. It has been
reported in the literature that the reason PBDs are only active
against Gram-positive bacteria is due to their inability to cross
Gram-negative membranes.16 We designed and synthesized a
new generation of C8-PBD monomers with an aliphatic third
ring that showed, for the first time, notable activity against
Gram-negative bacteria. The introduction of the aliphatic third
ring improved the prokaryotic selectivity of the molecules and
reduced eukaryotic toxicity of the molecules, as the third ring
interfered with the DNA binding ability of these molecules.
The synthesized compounds showed a broad-spectrum
activity against both MDR and PDR clinical ESKAPE strains
with minimum inhibitory concentrations (MICs) ranging from
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0.03 to 1 mg/L against Gram-positive species and from 0.125
to 32 mg/L against Gram-negative species. The compounds
demonstrated a rapid bactericidal mode of action against both
Gram-positive and Gram-negative species. The mechanism of
action of this type of compound was explored both in silico and
through a range of microbiological techniques. These methods
suggest that the inhibition of DNA gyrase is one of the main
mechanisms of action, although the possibility of activity
through other mechanisms cannot be completely ruled out.
The efflux liability and entry into Gram-negative species of the
chemical series and the likelihood of the emergence of
resistance was also studied. Importantly, the relative lack of
DNA binding, as observed by fluorescence resonance energy
transfer (FRET)-based DNA melting, combined with the
absence of eukaryotic toxicity, highlights the potential
therapeutic value of this new type of C8-linked PBD
monomers as antibacterial compounds.
■ RESULTS AND DISCUSSION
Design and Synthesis of PBD Monomers. Three C8-
linked biaryl-PBD monomers with reported activity against
Gram-positive species were selected as the starting point for
the medicinal chemistry modification (Figure 1). These
monomers contain C8-substituents with two heteroaromatic
or biaryl building blocks connected via amide bonds. The side
chains were elongated with a third aliphatic heterocycle,
resulting in an unconventional class of PBD derivatives that
Figure 1. Reported antibacterial PBDs and structural modification employed to obtain compounds with activity against Gram-negative bacteria.
Figure 2. Structure of control compounds 1 and 2 and structures of final compounds 3−17.
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have never been investigated before. Initially, three nitrogen-
containing aliphatic heterocycles, thiomorpholine, morpholine,
and piperidine, were introduced, and this was followed by
coupling the heteroaromatic ring containing PBD monomers
with diethyl and dimethylamine. The structural modification
aimed to modify the physicochemical properties of the
molecules and occupy a different chemical space, as polar
compounds have traditionally shown better activity against
Gram-negative bacteria.17 The secondary aim was to reduce
the DNA binding affinity of the compounds to minimize
eukaryotic toxicity, as the replacement of an aromatic group
with an aliphatic ring was expected to reduce both interaction
and fit of the molecules within the DNA minor groove. A total
of 15 target compounds were designed and successfully
synthesized to explore the structure−activity relationship
(SAR) (Figure 2) and understand the role of the third rings
in extending the antibacterial activity of the compounds. C8-
linked monomers 1 (GWL-78) and 2, in which the
heteroaromatic pyrrole ring replaced the third aliphatic ring,
were used as the control to compare their activity against
Gram-negative bacteria.
The target compounds were synthesized using a convergent
strategy based on literature-reported procedures. The synthetic
process is based on the C8 derivatization of an alloc,
tetrahydropyran (THP)-protected PBD core with different
polyamide side chains. The protected PBD core 26 was
synthesized in nine steps starting from vanillin accordingly to a
reported procedure from our group (Figure 3). The synthetic
methods and characterization of intermediates that lead to 26
are included in the Supporting Information file (chemistry
section). The three-component side chains were synthesized
by the sequential addition of the different constituents via
amide coupling. Alternative strategies based on either the use
of protecting groups or functional groups interconversion were
employed to avoid side reactions. For the synthesis of
benzofused containing lateral chains (Scheme 1), the initial
step involved the formation of an amide bond between Boc-
protected N-methyl pyrrole carboxylic acid and the corre-
sponding 5-amino benzofused methyl ester to give inter-
Figure 3. Synthetic approach to obtain antibacterial PBD monomers.
Scheme 1. Synthesis of C8 Benzofused Lateral Chains 29−38a
aReagents and conditions: (a) EDCI, DMAP, DMF, r.t., overnight; (b) NaOH, MeOH, H2O, r.t., overnight then EDCI, DMAP, DMF, r.t.,
overnight; (c) NaOH, MeOH, H20, r.t., overnight then T3P, DIPEA, DMF, r.t., overnight.
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mediates 27 and 28. The ester derivative underwent basic
hydrolysis to give the carboxylic acids that were successfully
coupled with diethylamine, piperidine, morpholine, or
thiomorpholine to give the complete C8-side chains 31−38.
The coupling system EDCI/DMAP was used as the reagent for
the formation of the amide bonds with good yield with the
only exception of diethylamine products. In this case, the
coupling between the carboxylic acid derivatives of 27 and 28
and the secondary amine was performed using a propylphos-
phonic anhydride (T3P)-sustained dehydration reaction in the
presence of N,N-diisopropylethylamine (DIPEA). The syn-
thesis of dimethylamine derivatives 29 and 30 was
accomplished with direct coupling between Boc-protected N-
methyl pyrrole carboxylic acid and corresponding commer-
cially available 5-amino benzofused dimethyl carboxamides.
The coupling system EDCI/DMAP was used for the formation
of the amide bond similar to previous examples.
Two different approaches were employed, depending on the
aliphatic substitution of the products, for the synthesis of
methylpyrrole benzenamine (MPB) containing lateral chains
(Scheme 2). In the case of piperidine, morpholine, and
thiomorpholine substitution, the MPB central building block
39 was synthesized via Suzuki coupling between Br-methyl
pyrrole carboxylic acid and the para-Boc-protected benzen-
amine boronic acid. After acid-catalyzed Boc-deprotection, the
aniline derivative of 39 underwent the amide coupling reaction
with Boc-protected N-methyl pyrrole carboxylic acid. The
reaction was performed with an EDCI/DMAP coupling system
to give intermediate 40. The synthetic process was completed
by basic hydrolysis of the methyl ester moiety, and successive
EDCI/DMAP sustained amide coupling reaction with
piperidine, morpholine, or thiomorpholine to give complete
side chains 41−43, respectively. This synthetic approach failed
in the formation of dimethyl and diethyl amide derivatives
because of the poor yield of the amide coupling reaction of the
considered secondary amines using traditional coupling
reagents.
For this reason, a reverse-direction synthetic process, with
aliphatic derivatization as the first step, was applied for the
synthesis of dimethyl and diethyl-substituted MPB containing
side chains. Specifically, the synthetic route was modified with
the initial synthesis of dimethyl and diethyl N-methyl Br
pyrrole intermediates 44 and 45 via amide bond formation
based on acyl chloride formation. Commercially available 4-Br-
N-methyl pyrrole methyl ester was hydrolyzed, and the
corresponding carboxylic acid was activated to acyl chloride
using oxalyl chloride in the presence of catalytic dimethylfor-
mamide (DMF). The reaction mixture was then treated with
the corresponding secondary amine to give the desired
product.
Intermediates 44 and 45 underwent the Suzuki coupling
reaction with para-Boc-protected benzenamine boronic acid to
give MPB-modified derivatives 46 and 47. The obtained
intermediates were deprotected via acid treatment and then
successfully coupled with Boc-protected N-methyl pyrrole
carboxylic acid to give final complete lateral chains 48−49.
Scheme 2. Synthesis of C8 MPB Containing Lateral Chains 41−43 and 49−49a
aReagents and conditions: (a) tetrakis(triphenylphospine)Pd, K2CO3, ACN, H2O, MW irradiation, 100 °C, 6 min; (b) EDCI, DMAP, DMF, r.t.,
overnight; (c) NaOH, MeOH, H2O, r.t., overnight then EDCI, DMAP, DMF, r.t., overnight; (d) oxalyl chloride, DMF, dry DCM, Et3N, r.t.,
overnight; (e) HCl 4 M in dioxane, MeOH, r.t., 30 min then EDCI, DMAP, DMF, r.t., overnight.
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Finally, the convergent synthetic strategy was completed
with the coupling of C8-side chains 29−38, 41−43, and 48−
49 to the PBD core 26 using EDCI/DMAP-mediated amide
coupling. This reaction was followed by the palladium-
catalyzed deprotection of allyl carbamate moiety and concerted
THP deprotection of the alcohol moiety to generate the
reactive N10−C11 imine bond, giving the final products 3−17
(Scheme 3).
Screening of PBDs To Define SAR. Bacterial panels
containing drug-sensitive and MDR strains of Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
Staphylococcus aureus, and Enterococcus spp. were used as an
initial screen to determine the efficacy of the PBD compounds
in this series and establish a SAR (Tables 1 and 2) (resistance
profiles for all strains are in Table S1). All of the designed PBD
molecules had a third aliphatic ring or a ring fragment and
contained pyrrole as the first unit followed by MPB,
benzofuran, or benzothiophene as the second unit. Against
the Gram-negative species tested, the control PBD molecule 2
did not show any notable activity, with MICs ranging from 64
to >128 mg/L (Table 1). However, the aliphatic third ring
containing C8-linked PBDs (compounds 3−17) showed
notable improvement in activity against Gram-negative
bacteria, except for P. aeruginosa, with MICs as low as 0.5
mg/L against MDR A. baumannii and K. pneumoniae strains.
Compounds bearing GC-targeting methylphenylbenzen-
amine (MPB) substituent as a central group (compounds 13,
15 to 17) showed good efficacy against A. baumannii and K.
pneumoniae but were inactive against P. aeruginosa. Com-
pounds containing benzofuran as the second ring were found
to be more active than the corresponding benzothiophene
series. The structural modification of the third aliphatic ring
showed a significant influence on the activity of the
compounds. In all cases, compounds with thiomorpholine
with the third ring (example compounds 7, 12, and 17) had
MICs of ≤2 mg/L against the A. baumannii strains tested. The
presence of a second heteroatom in the aliphatic third ring
improved activity, but intriguingly, shortening the third ring to
a dimethyl or diethyl side chain (example compounds 3, 4, 8,
9, and 13) retained activity, with dimethyl analogues showing
better activity than their diethyl counterparts, except for
compounds containing the MPB ring in which diethyl
substitution, compound 14, resulted in loss of activity.
Against the Gram-positive species tested, all compounds,
including the control PBD molecule, showed excellent activity,
with MICs ranging from ≤0.03 to 2 mg/L (Table 2).
Two compounds (7 and 8) with promising activity against
both Gram-negative and Gram-positive strains were selected
for further screening against a wider panel of bacteria including
MDR Gram-negative strains of Escherichia coli, A. baumannii,
K. pneumoniae, and Burkholderia cepacia/cenocepacia complex.
The K. pneumoniae strains selected for the study were resistant
Scheme 3. Synthesis of PBD monomers 3−17a
aReagents and conditions: (a) HCl 4 M in dioxane, MeOH, r.t., 30 min then EDCI, DMAP, DMF, r.t., overnight; (b) tetrakis(triphenylphospine)-
Pd, piperidine, triphenylphospine, DCM, r.t., 30 min.
Table 1. Activity of the Synthesized Compounds against
Gram-Negative Bacteria (mg/L)
A. baumannii K. pneumoniae P. aeruginosa
resistance








1 128 128 >128 >128 128 >128
2 64 64 128 128 >128 128
3 4 4 0.5 16 128 64
4 4 4 8 64 128 32
5 2 2 8 64 128 32
6 8 8 0.5−1 32−64 >128 64
7 2 2 1 32 >32 >32
8 1 0.5 1 2 >32 >32
9 2 2 8 64 128 32
10 8 8 128 128 128 64
11 8 8 64 8 64 32
12 2 2 >128 2 64 32
13 4 4 2 8 128 >128
14 64 32 >128 >128 >128 >128
15 2 2 16 >128 >128 >128
16 4 2 2 32 >128 >128
17 2 2 4 >32 >32 >32
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://dx.doi.org/10.1021/acs.jmedchem.0c00328
J. Med. Chem. 2020, 63, 6941−6958
6945
against most marketed antibiotics (Tables 3 and S1) including
one essentially PDR strain (51851). Similarly, the A. baumannii
strains and E. coli strains containing extended spectrum β
lactamase (ESBL) and carbapenemase genes were resistant to
six to eight clinically used antibiotics (Table S1). Both
compounds were found to be active against almost all strains
tested except for Burkholderia multivorans C1962 against which
compound 7 was found to be inactive (defined here as an MIC
> 32 mg/L). The levels of activity observed, considering the
high levels of intrinsic or acquired resistance in many of these
strains, are exceptional, with low and in some cases sub μM
MICs. Notably, compound 8 exhibited a range of MICs from
0.25 to 2 mg/L for K. pneumoniae, 0.125 to 1 mg/L for A.
baumannii/baylyi, 0.5 to 1 mg/L for E. coli, and 0.125 to 2 mg/
L for B. cepacia complex. These values are exciting and suggest
that this represents a promising new chemical scaffold that can
be further developed as broad-spectrum antibiotics.
Defining the Mode of Action of PBDs through Time-
Kill Assays. The mode of action of compounds 7 and 8 was
explored using time-kill assays. Three K. pneumoniae (NCTC
13368, 16 and NCTC 13438) and three A. baumannii (AYE,
ATCC 17978 and NCTC 13424) strains were selected for
time-kill analysis (Figure 4). These strains were selected to
provide a range of drug resistance profiles from a relatively
drug-sensitive strain (ATCC 17978), through MDR strains
with multiple resistance mechanisms (NCTC 13438, 16 and
NCTC 13424) for each species. Compound 8 was rapidly
bactericidal in all strains tested; the viable count was below the
limit of detection (LOD) within 4 h and continued to be
below the LOD for the full assay for all K. pneumoniae strains
challenged with 8, indicating that there was no resistance to
this compound within the 24 h period of the assay. A small
number of viable cells were observed at the end of 24 h for A.
baumannii strains AYE and NCTC 13424 (Figure 4).
Subsequent testing with 8 on these populations showed no
increase in MIC above wild-type levels, and these populations
were not considered to be resistant (results not shown).
Compound 7 was also bactericidal against the majority of
Table 2. Activity of the Synthesized Compounds against MDR Gram-Positive Bacteriaa
E. faecium E. faecalis S. aureus
resistance profiles MDR (VRE) S (VSE) MDR (MRSA) S (MSSA)
compound NCTC 12204 NCTC 12201 NCTC 775 NCTC 13616 NCTC 13277 NCTC 6571
1 0.5 0.5 1 1 2 0.5
2 ≤0.125 ≤0.125 ≤0.125 0.5 1 ≤0.125
3 ≤0.125 0.5 ≤0.125 ≤0.125 ≤0.125 ≤0.125
4 ≤0.125 ≤0.125 0.25 0.25 0.5 ≤0.125
5 ≤0.125 ≤0.125 0.25 0.25 0.5 ≤0.125
6 ≤0.125 ≤0.125 ≤0.125 ≤0.125 0.25 ≤0.125
7 0.03 0.25 1 2 2 0.5
8 0.03 0.03 0.03 0.03 0.06 0.03
9 1 0.5 1 1 1 0.5
10 ≤0.125 ≤0.125 0.25 0.5 1 ≤0.125
11 ≤0.125 ≤0.125 ≤0.125 ≤0.125 0.5 ≤0.125
12 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.125
13 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.125
14 0.25 0.25−0.5 0.5 1 1 0.25−0.5
15 ≤0.03 ≤0.03 0.125 0.06 0.125 ≤0.03
16 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.125
17 ≤0.03 ≤0.03 ≤0.03 ≤0.03 0.06 ≤0.03
aMICs are expressed in mg/L.
Table 3. Activity of Compounds 7 and 8 against an





K. pneumoniae NCTC 13368 2 32
M6 1 1
NCTC 13438 0.5 4−8
NCTC 13439 2 4−8




MGH 78578 1 4−8
A. baumannii ATCC 17978 0.5 2
AYE 1 2
NCTC 13424 0.5 1
ADP1 0.125 1










NCTC 12923 0.5 2
B. multivorans C1576 1 16
C1962 2 >32
B. cenocepacia K56-2 2 1
B. cepacia CEP509 2 8
NCTC 17765 0.125 1
LMG 17997 0.125 0.25
NCTC 10743 1−2 16
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strains tested, although the speed of killing was slower than
compound 8 in a number of cases (NCTC 13438, AYE,
NCTC 13424). In the case of K. pneumoniae NCTC 13368,
which had a much higher intrinsic resistance to compound 7,
only a small reduction in viable count was observed at 6 h, with
bacterial numbers returning to the levels of the untreated
control by 24 h, in two out of three replicate experiments.
When these bacteria were isolated, passaged 10× in the
absence of selection and re-assayed, the MICs increased for
both compound 7 (32 to ≥128 mg/L) and compound 8 (2 to
>32 mg/L). No increases in MIC were observed for other
antibiotics, including aminoglycosides, fluoroquinolones, and
β-lactams, except for an increase in colistin resistance of 4−32
mg/L in one of the two isolates (Table S2).
Evaluation of the Influence of Efflux and Influx on
the Activity of the PBD Compounds. Two efflux pump
inhibitors (EPIs), PAβN (used in the presence of Mg2+ to
prevent nonspecific effects on membrane permeability)18
which competitively inhibits specific resistance nodulation
division (RND) efflux pumps and carbonyl cyanide m-
chlorophenyl hydrazone (CCCP), which inhibits the proton
motive force, were used to assess the impact of efflux on the
activity of the lead compounds against wild-type bacterial
strains, together with the resistant mutants isolated from the
time-kill experiments.
The result (Table 4) suggests that both compounds are
substrates for RND-family efflux pumps, but the presence and/
or expression of specific efflux pumps differs between the
strains tested. To investigate this further, specifically in the P.
aeruginosa strain PAO1, transposon mutants in various RND
efflux pumps were obtained from the Manoil collection (Univ.
Washington; Table S3). Transposon mutants in any
component of the tripartite RND efflux system MexAB-
OprM reduced the MIC by ≥8-fold for both compounds 7 and
8. The MIC of compound 8 was also decreased ≥4-fold by
transposons in MexCD but not its outer membrane
component OprJ; no such effect was observed for compound
7 with transposon mutants in any component of this pump.
A membrane permeabilizer, polymyxin B nonapeptide
(PMBN), used at a concentration which did not affect
Figure 4. Rapid bactericidal kill by synthesized compounds 7 and 8, with occasional breakthrough resistance in some drug−strain combinations.
The data are the average of three independent experiments, and error bars represent the standard deviation from the mean.
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bacterial growth in its own right, was also used to understand
to what extent efficacy for compounds with high MICs was
impacted by entry of the compounds into the cell. Effects in P.
aeruginosa were particularly marked, with the addition of
PMBN reducing the MIC of 8 against the MDR strain NCTC
13437 from >32 to ≤0.03−1.0 mg/L, a reduction of between
32- and 1000-fold. Similarly, a reduction in MIC against PAO1
was observed between 4- and ≥16-fold for compound 8.
Table 4. Inhibiting Efflux and Increasing Influx Potential Reduces the MIC for Selected Compounds in Strains of K.
pneumoniae, A. baumannii, and P. aeruginosaa
≤
aA fourfold change in MIC in the presence of efflux inhibitors or membrane permeabilizers was defined as significant (highlighted by shading). All
values are given in mg/L. These data are representative of three or more independent experiments. ND = Not done.
Figure 5. Molecular model showing the location of the binding pocket and the interaction of compound 7 with (A) DNA gyrase A from S. aureus;
(B) DNA gyrase A from E. coli.
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PMBN also reduced the MIC of compound 7 against an
extended panel of P. aeruginosa strains from >32 to 1−8 mg/L
(8- to ≥64-fold). The activity of these compounds in P.
aeruginosa strains in the presence of a permeabilizer shows that
these compounds are effective at killing strains once they are
able to cross the outer membrane barrier. This offers the
opportunity to optimize the active compounds using
medicinal-chemistry modifications or to explore active delivery
mechanisms to allow the compounds to permeate the
Pseudomonas membrane.
Understanding the Mechanism of Action. Effect of the
Aliphatic Third Ring Substitution on DNA Binding and
Eukaryotic Toxicity of the Synthesized Compounds. The
cytotoxicity of C8-linked PBD monomers is linked with their
ability to stabilize DNA sequences. A FRET-based DNA
melting assay7 was used to explore the effect of the aliphatic
third ring on the DNA stabilization property of the newly
synthesized molecules. Two fluorophore labeled oligonucleo-
tides (sequence F1: 5′-FAM-TAT-ATA-TAG-ATA-TTT-
TTT-TAT-CTA-TAT-ATA-3′-TAMRA and sequence-F2: 5′-
FAM-TAT-AGA-TAT-AGA-TAT-TTT-ATA-TCT-ATA-
TCT-ATA-3′-TAMRA) with preferred PBD binding sites were
used in the assay, and the stabilization was compared with a
previously reported C8-PBD monomer, GWL-7819 (com-
pound 1) and the control compound 2 with the third
heteroaromatic ring. In all cases, compounds with aliphatic
third moiety showed between 3- and 4-fold lower ΔTm values
at both 5:1 and 1:1 ligand−DNA ratios compared to the
control compounds, showing that the introduction of the
aliphatic third moiety reduced the ability of these compounds
to interact with and stabilize the DNA sequences (Table S4).
The eukaryotic toxicity of the synthesized PBD derivatives was
tested at a single concentration (20 μM) using the MTT
viability assay on WI-38 fibroblast cell line. The control
compounds, 1 and 2, showed potent cytotoxicity with only 35
and 32% of cells viable after 24 h. However, the newly
synthesized compounds showed notably less toxicity, with
>85% of cells viable after 24 h of treatment with the molecules
(Figure S1). Considering an average molecular weight of 700
Da for the synthesized PBD monomers, the concentration used
for the test (20 μM) corresponds to a concentration of 14 mg/
L, which is approximately 100 times the average MIC reported
for Gram-positive strains and almost 10 times the average MIC
reported for Gram-negative strains for active compounds. The
obtained results confirmed the presence of a selective toxicity
profile toward prokaryotic cells for the PBD-C8 conjugates,
confirming the possibility of further development of this class
of compounds as antibacterial agents.
Inhibition of DNA Gyrase. The C8-linked PBDs have been
recently reported as DNA gyrase inhibitors.14 This was further
explored by docking compounds 7 and 8 with the bacterial
gyrase from S. aureus (PDB ID 2XCT) and E. coli (PDB ID
6RKS) (Figures 5 and S2). Both compounds bound to the
ligand binding domain of DNA gyrase A and showed
interaction with several amino acid residues through hydrogen
bonds and hydrophobic interactions. The best pose of
compound 7 gave a ChemScore of 27.62 and a binding
affinity of −31.67 kcal/mol, and the values for compound 8
were comparable with a ChemScore of 27.35 and binding
affinity of−30.70 kcal/mol in the case of DNA gyrase A from S.
aureus. For the DNA gyrase A from E. coli, the ChemScores
were 25.16 and 22.01 while the free energy of binding values
were 30.46 and −25.51 kcal/mol for compounds 7 and 8,
respectively. The 2D models shown in Figure S3 suggest that
compound 7 forms six hydrogen bonds within the ligand
binding domain of DNA gyrase A from S. aureus and five
hydrogen bonds within the ligand binding domain of DNA
gyrase A from E. coli. Similarly, compound 8 forms five
hydrogen bonds within the ligand binding domain of DNA
gyrase A from S. aureus and four hydrogen bonds within the
ligand binding domain of DNA gyrase A from E. coli. Both
compounds show notable hydrophobic interaction within the
binding site (Tables S5−S8). The interaction of compounds 7
and 8 with the ligand binding sites of gyrase A suggests that the
inhibition of gyrase A plays a crucial role in the antimicrobial
activity of this class of compound.
We have recently shown that PBD monomers caused the
inhibition of DNA gyrase in a rapid assay format.14 A gel-based
assay was used here to evaluate whether compounds 7 and 8
were also able to inhibit DNA gyrase in vitro. In assays using
purified S. aureus DNA gyrase, compound 8 showed an IC50 of
3.16 ± 1.36 mg/L compared to ciprofloxacin IC50 of 13.05 ±
1.36 mg/L (Figure 6). It was not possible to determine an IC50
for compound 7, as solubility issues prevented the use of high
enough concentrations of compound to achieve >50%
inhibition (at a concentration of 32 mg/L). Against the E.
coli DNA gyrase, it was not possible to reach a concentration
high enough to achieve greater than 50% inhibition for either
compound 7 or 8, again because of solubility issues. The
relative inhibition of the Gram-positive versus Gram-negative
gyrase correlates with the relatively higher MICs of Gram-
negative bacteria species, and this supports the idea that the
novel PBDs described here work through the inhibition of
DNA gyrase.
Although we have evidence of the inhibition of DNA gyrase
activity, for both Gram-positive and Gram-negative DNA
gyrase, this does not preclude the possibility that the PBDs
cause inhibition via binding to DNA and/or a DNA−gyrase
complex. To further define the mechanism of action, a panel of
fluorescent E. coli reporter strains was used to understand the
profile of cellular responses to PBDs and compare these with
Figure 6. Inhibition of gyrase enzyme from (A) S. aureus and (B) E.
coli by synthesized compounds 7 and 8 and the control, ciprofloxacin.
Results represent the mean of three independent experiments, and the
error bars are the standard deviation of the mean.
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molecules with known mechanisms of action. A panel of strains
derived from a comprehensive library of E. coli promoter
fusions was used.20 Specific reporters for compounds affecting
the DNA metabolism were selected, in line with previous
studies,21 and validated with DNA gyrase inhibitors
(fluoroquinolones, novobiocin), compounds known to bind
DNA (mitomycin C, PBD control) and control compounds
affecting other cellular targets (doxycycline, ampicillin,
rifampicin). The four promoter fusions showed the expected
induction with fluoroquinolones (specifically levofloxacin,
ciprofloxacin, norfloxacin, and moxifloxacin) and the quino-
lone antibiotic nalidixic acid, associated with the activation of
the bacterial SOS response as a result of the poisoning of the
DNA gyrase. The level of fold induction was similar between
the known gyrase inhibitors, with fold inductions ranging from
20- to 35-fold for recA, 5- to 13-fold for lexA, 14- to 32-fold for
recN, and 17- to 41-fold for sulA (Figure 7). Although
compounds 7 and 8 both showed the activation of the same
four promoter fusions, the levels were significantly lower for
each of the genes (8−10-fold recA, 5−9-fold lexA, 6−11-fold
recN, and 6−7-fold sulA). By comparison, the three antibiotics
known not to induce the SOS response, doxycycline,
rifampicin, and ampicillin, showed no induction of any of the
four promoters above the level of the control strain.
Interestingly, three compounds showed similar levels of
activation of the promoters to the two PBDs. Two of these
are known to be DNA binding molecules, mitomycin C and
the control PBD dimer DSB-120,22 whereas the third,
novobiocin, inhibits DNA gyrase by interaction with the
ATP-binding site on the GyrB subunit. These results suggest
that the PBDs act by interfering with DNA metabolism, in a
way that is clearly different from fluoroquinolones. This is
consistent with MIC data which show no significant differences
between fluoroquinolone-sensitive and -resistant strains.
Further studies will be required to delineate the specific
interactions with DNA and/or individual gyrase subunits and
the specific mechanisms of inhibition.
Emergence of ResistanceMutation Frequency. The
mutation frequency of the most active compound 8 was tested
against representative strains of the three Gram-negative
pathogens in comparison with ciprofloxacin. At 4× MIC,
mutation frequencies of <4.3 × 10−8 and <1.5 × 10−8 were
measured across three replicate experiments for NCTC 12923
and ATCC 17978, respectively. In both cases, the values were
significantly lower than the control antibiotic, ciprofloxacin
(4.4 × 10−7 for NCTC 12923 and 8.4 × 10−7 for
ATCC17978). This was not the case in the K. pneumoniae
isolate M6, where the mutation frequency was 1.0 × 10−6 for
compound 8, compared to 8.9 × 10−7 for ciprofloxacin. This
higher mutation frequency is reflected in the time-kill
experiments, where resistance was only seen in a single K.
pneumoniae strain (NCTC 13368), following exposure to
concentrations above the MIC and not in A. baumannii.
The mutations associated with resistance in NCTC 13368
were identified by whole genome sequence analysis of stable
resistant isolates. In one of the time-kill repeats, the resistant
strains showed the deletion of a single base in position 50 of a
gene encoding a predicted nucleoside-specific channel-forming
protein (KPN_RS01945), termed Tsx. The mutation caused a
frameshift in the tsx gene and was predicted to result in a
truncated 42 amino acid protein. A second SNP was also
identified in another uncharacterized permease gene, leading to
an amino acid change M137K. A clean transposon mutant
(tnkp1_lr150124p14q189) in tsx, in K. pneumoniae strain
MKP103, also showed elevated resistance to compounds 7 and
8, with respect to their parental strain (compound 7 from 32
mg/L in wild-type to >128 mg/L for tsx transposon, and for
compound 8 from 16 to >32 mg/L) (Table S3). The Tsx
protein has previously been described as mediating resistance
to the antibiotic albicidin in Klebsiella oxytoca.23 A second
resistant NCTC 13368 isolate showed a SNP, leading to an
amino acid change H50N in a predicted MerR family regulator
(KPN_RS12075).
■ CONCLUSIONS
The lack of new antibiotics, especially for rapidly emerging
MDR Gram-negative pathogens, is a significant cause for
concern. Several studies have suggested that there may be no
new antimicrobials, with distinct modes of action, available for
treatment of these pathogens for a considerable time.24 Against
this background, we report the identification of a new scaffold
with significant activity against both Gram-positive and MDR
Gram-negative pathogens, which do not appear to be impacted
by common resistance mechanisms to other broad-spectrum
antibiotics, and with a low mutation frequency, leading to
resistance in key species such as A. baumannii and E. coli.
Mechanistic evaluation shows a sub-micromolar IC50 in a
gel-based S. aureus DNA gyrase assay, significantly lower than
ciprofloxacin and not affected by GyrA mutations associated
with fluoroquinolone resistance. Using a panel of fluorescent
reporters, it was possible to show the activation of genes which
are associated with the SOS response in Gram-negative
bacteria, but again the magnitude of promoter activation
differed from fluoroquinolones and was consistent with both
known DNA binders (e.g., mitomycin C) and DNA gyrase
inhibitors that act via alternative binding sites to fluoroquino-
lones (e.g., novobiocin).
The compounds show excellent activity against WHO
priority pathogens with an in vitro selective index which
would allow their continued development. The developability
assessment of the lead compounds will be carried out to fully
explore the clinical utility of this chemical class. There is
renewed interest in developing bacteria-specific ADCs. We
intend to exploit well-understood and clinically validated
routes to develop ADCs, which has been successfully
employed for PBD-type compounds in oncology, to further
Figure 7. Reporter assay to explore the mechanism of action of
compounds 7 and 8. Data are the mean of three independent
experiments, and error bars represent the standard deviation of the
mean. Two-way ANOVA and Dunnett’s multiple comparison tests
were performed and included here for reporter strain recA, all
compounds were compared to ciprofloxacin ****p < 0.0001.
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improve the prokaryotic selectivity of these compounds and to
provide selective targeting of such compounds to bacteria. This
will form the basis of broad-spectrum PBD antibiotics which
may have significant utility in the clinic.
■ EXPERIMENTAL SECTION
General Chemistry. All reagents and solvents employed in the
synthetic processes were obtained from commercially available
sources including, among others, Sigma-Aldrich, Fisher Scientific,
Fluorochem, and Alfa Aesar. 1H and 13C nuclear magnetic resonance
(NMR) analyses were performed on a Bruker Spectro Spin 400 Hz
spectrometer. Liquid chromatography−mass spectrometry (LC−MS)
analyses were performed on a Waters Alliance 2695 system, eluting in
gradient. The analyses were performed on a Monolithic C18 50 ×
4.60 mm column by Phenomenex. UV detection was performed on a
diode array detector. Mass spectra were registered in both ESI+ and
ESI− modes. Melting points were determined using a Stuart SMP30
melting point apparatus. All of the compounds tested for their
biological activity are >95% pure, that is confirmed with two different
high-performance LC analysis methods. The high-resolution MS
(HRMS) analyses were performed on a Thermo Scientific Exactive
HCD Orbitrap Mass Spectrometer. The hydrogenation reaction was
conducted using a Parr hydrogenation system. Synthetic protocols
and compound characterization for the previously reported PBD core
are reported in the Supporting Information file.
Synthesis of Pyrrole Benzofused Intermediates 27 and 28.
Commercially available 4-((tert-butoxycarbonyl)amino)-1-methyl-
1H-pyrrole-2-carboxylic acid (200 mg, 0.8 mmol, 1.2 equiv) was
dissolved in DMF (5 mL). EDCI (2.5 equiv) and DMAP (3 equiv)
were added to the solution that was left under a magnetic stirrer in a
N2 atmosphere for 20 min. At that point, the corresponding 5-amino-
2-methyl ester benzofused (1 equiv) was added to the reaction
mixture and left under a magnetic stirrer overnight. The reaction did
not go to completion. The reaction was quenched by the addition of
water (15 mL) that was then extracted with ethyl acetate (3 × 10
mL). The organic phase was then sequentially washed with brine (15
mL), NaHCO3-saturated aqueous solution (15 mL), and citric acid
aqueous solution 0.1 M (15 mL). The collected organic phase was
dried on MgSO4 and subsequently evaporated using a rotary
evaporator giving crude of reaction that was subsequently purified
by column chromatography [mobile phase: from 100 dichloro-
methane (DCM) to 85/15, v/v, DCM/EtOAc] to give the final
products 27 and 28.
6-(4-((tert-Butoxycarbonyl)amino)-1-methyl-1H-pyrrole-2-
carboxamido)benzofuran-2-carboxylate (27). Obtained 0.200 g
(reaction yield: 70%) as a yellow solid. 1H NMR (400 MHz,
chloroform-d): δ 8.09 (d, J = 2.01 Hz, 1H), 7.85 (s, 1H), 7.51 (d, J =
9.06 Hz, 1H), 7.47 (s, 1H), 7.40 (dd, J = 9.06 Hz, 2.27 Hz, 1H), 6.86
(br s, 1H), 6.70 (br s, 1H), 6.43 (br s, 1H), 3.97 (s, 3 H), 3.91 (s, 3
H), 1.51 (s, 9H). 13C NMR (101 MHz, chloroform-d): δ 159.9,
159.7, 152.5, 146.2, 134.0, 127.4, 123.3, 121.9, 121.3, 118.8, 114.2,
113.8, 112.6, 103.9, 80.4, 52.5, 36.8, 28.4. m/z: (ESI+) calcd for
C21H23N3O6 (M)
+, 413.1; found, 414.0 ([M] + H)+.
Methyl 5-(4-((tert-Butoxycarbonyl)amino)-1-methyl-1H-pyrrole-
2-carboxamido) benzo[b]thiophene-2-carboxylate (28). Obtained
0.192 g (reaction yield: 65%) as a yellow-orange solid. 1H NMR (400
MHz, chloroform-d): δ 8.24 (d, J = 1.76 Hz, 1H), 7.97 (s, 1H), 7.78−
7.76 (m, 2H), 7.49 (dd, J = 8.69, 2.14 Hz, 1H), 6.86 (br s, 1H), 6.70
(br s, 1H), 6.33 (br s, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 1.52 (s, 9H).
13C NMR (100 MHz, chloroform-d): δ 163.2, 159.7, 153.5, 139.3,
137.7, 135.5, 134.4, 130.5, 123.3, 123.0, 122.0, 120.6, 119.0, 115.9,
104.1, 80.4, 52.5, 36.7, 28.3. m/z: (ESI+) calcd for C21H23N3O5S
(M)+, 429.1; found, 430.0 ([M] + H)+.
tert-Butyl(5-((2-(dimethylcarbamoyl)benzofuran-5-yl)-
carbamoyl)-1-methyl-1H-pyrrol-3-yl)carbamate (29). Obtained
0.190 g (reaction yield: 72%), as a yellow solid. 1H NMR (400
MHz, chloroform-d): δ 7.99 (d, J = 2.01 Hz, 1H), 7.70 (s, 1H), 7.48
(d, J = 8.81 Hz, 1H), 7.38 (dd, J = 8.94, 2.14 Hz, 1H), 7.25 (d, J =
0.76 Hz, 1H), 6.88 (s, 1H), 6.68 (s, 1H), 6.32 (s, 1H), 3.92 (s, 3H),
3.35 (br s, 3H), 3.15 (br s, 3H), 1.52 (s, 9H). 13C NMR (101 MHz,
chloroform-d): δ 160.9, 159.8, 153.4, 151.5, 150.0, 133.8, 127.5,
123.4, 121.9, 120.0, 118.7, 113.5, 112.1, 111.9, 103.8, 80.4, 36.8, 28.4.
m/z: (ESI+) calcd for C22H26N4O5 (M)




0.130 g (reaction yield: 60%), as a brown solid. 1H NMR (400
MHz, chloroform-d): δ 8.25 (d, J = 2.01 Hz, 1H), 7.70−7.81 (m,
2H), 7.46 (s, 1H), 7.36 (dd, J = 8.69, 2.14 Hz, 1H), 6.88 (br s, 1H),
6.70 (br s, 1H), 6.33 (br s, 1H), 3.93 (s, 3H), 3.22 (br s, 6H), 1.52 (s,
9H). 13C NMR (101 MHz, chloroform-d): δ 164.8, 159.7, 153.5,
139.4, 138.7, 135.8, 135.2, 125.5, 123.3, 122.7, 122.0, 119.3, 118.8,
115.3, 103.9, 80.4, 36.8, 28.4. m/z: (ESI+) calcd for C22H26N4O4S
(M)+, 442.1; found, 443.1 ([M] + H)+.
Synthesis of Benzofused Side Chains 31 to 38. The selected
benzofused methyl ester intermediate 27 or 28 (1 equiv) was
dissolved in MeOH (8 mL), and an excess of NaOH 1 M aqueous
solution was added to the solution. The reaction mixture was left
under a magnetic stirrer overnight at room temperature until thin-
layer chromatography (TLC) showed total disappearance of the
starting material. The solvent was evaporated under vacuum using a
rotary evaporator, and citric acid 1 M aqueous solution was added to
the crude of the reaction until acid pH was reached causing the
simultaneous precipitation of a white solid. The precipitate was
collected by filtration under vacuum and dissolved in DMF (4 mL).
EDCI (2.5 equiv) and DMAP (3 equiv) were added to the solution,
and the reaction mixture was left under a magnetic stirrer for 20 min
at room temperature under a N2 atmosphere. Change in color of the
solution was observed from light yellow to dark brown. The
correspondent amine (1.5 equiv) was added to the solution and left
under a magnetic stirrer overnight. The reaction did not go to
completion. The reaction was quenched by the addition of H2O (10
mL) that was subsequently extracted with EtOAc (3 × 8 mL). The
collected organic phases were washed sequentially with brine (10
mL), NaHCO3-saturated aqueous solution (10 mL), and citric acid
aqueous solution 0.1 M (10 mL). The organic phase was dried on
MgSO4 and evaporated under vacuum using a rotary evaporator,
giving the correspondent crude of reaction that was purified by
column chromatography on silica gel (mobile phase: from 100 DCM
to 70/30, v/v, DCM/EA, depending on the substrate) to give the final
products 33−38.
In the case of diethyl derivatives 31 and 32, a different procedure
was applied. After the hydrolysis of the methyl ester benzofused
intermediates 27 and 28, the obtained acid (1 equiv) was dissolved in
DMF (4 mL), and diethyl amine (2 equiv) and DIPEA (2 equiv) were
added to the solution that was kept at 0 °C in an ice bath. At that
point, T3P (50% solution in DMF, 2 equiv) was added to the reaction
mixture that was allowed to reach room temperature and left under a
magnetic stirrer overnight. The reaction did not go to completion and
was quenched by the addition of water (10 mL) and then extracted
with ethyl acetate (3 × 8 mL). The organic phase was washed with
brine (10 mL) and NaHCO3-saturated aqueous solution (10 mL).
The collected organic phase was dried on MgSO4 and subsequently
evaporated under vacuum using a rotary evaporator. The crude of the
reaction was subsequently purified by column chromatography
(mobile phase: from 100 DCM to 70/30, v/v, DCM/EA) to give
the final products 31 and 32.
tert-Butyl(5-((2-(diethylcarbamoyl)benzofuran-5-yl)carbamoyl)-
1-methyl-1H-pyrrol-3-yl)carbamate (31). Obtained 0.036 g (reac-
tion yield: 40%) as a white solid. 1H NMR (400 MHz, chloroform-d):
δ 7.95 (d, J = 2.01 Hz, 1H), 7.80 (s, 1H), 7.34−7.47 (m, 2H), 7.23 (s,
1H), 6.88 (br s, 1H), 6.68 (br s, 1H), 6.43 (br s, 1H), 3.91 (s, 3H),
3.59 (br s, 4H), 1.51 (s, 9H), 1.29 (br s, 6H). 13C NMR (100 MHz,
chloroform-d): δ 160.3, 159.8, 153.5, 151.5, 150.5, 133.8, 127.5,
123.3, 121.9, 119.9, 118.7, 113.6, 111.9, 111.3, 103.9, 80.3, 36.7, 28.4,
14.2. m/z: (ESI+) calcd for C24H30N4O5 (M)
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0.035 g (reaction yield: 41%) as a white solid. 1H NMR (400 MHz,
chloroform-d): δ 8.20 (d, J = 2.01 Hz, 1H), 7.92 (br s, 1H), 7.69 (d, J
= 8.81 Hz, 1H), 7.37 (s, 1H), 7.31 (d, J = 8.81 Hz, 1H), 6.90 (br s,
1H), 6.70 (br s, 1H), 6.55 (br s, 1H), 3.89 (s, 3H), 3.55 (q, J = 7.22
Hz, 4H), 1.51 (s, 9H), 1.26 (t, J = 7.18 Hz, 6H). 13C NMR (100
MHz, chloroform-d): δ 164.2, 159.8, 153.5, 139.4, 138.8, 135.4, 135.3,
124.2, 123.2, 122.5, 122.0, 119.3, 118.9, 115.4, 80.2, 36.8, 28.4, 14.2.
m/z: (ESI+) calcd for C24H30N4O4S (M)
+, 470.2; found, 471.1 ([M]
+ H)+.
tert-Butyl(1-methyl-5-((2-(piperidine-1-carbonyl)benzofuran-5-
yl)carbamoyl)-1H-pyrrol-3-yl)carbamate (33). Obtained 0.031 g
(reaction yield: 34%) as a white solid. 1H NMR (400 MHz,
chloroform-d): δ 7.91−7.93 (m, 2H), 7.42 (d, 1H), 7.34−7.39 (m,
1H), 7.13 (d, J = 0.76 Hz, 1H), 6.88 (s, 1H), 6.68 (s, 1H), 6.55 (s,
1H), 3.88 (s, 3H), 3.72 (br s, 4H), 1.62−1.75 (m, 6H), 1.50 (s, 9H).
13C NMR (100 MHz, chloroform-d): δ 159.9, 159.8, 153.5, 151.3,
150.0, 133.9, 127.4, 123.3, 122.0, 120.0, 118.7, 113.5, 111.9, 111.2,
103.9, 80.2, 36.7, 28.4, 24.7, 24.6. m/z: (ESI+) calcd for C25H30N4O5
(M)+, 466.2; found, 467.1 ([M] + H)+.
tert-Butyl(1-methyl-5-((2-(piperidine-1-carbonyl)benzo[b]-
thiophen-5-yl)carbamoyl)-1H-pyrrol-3-yl)carbamate (34). Ob-
tained 0.032 g (reaction yield: 33%) as a yellow solid. 1H NMR
(400 MHz, chloroform-d): δ 8.20 (s, 1H), 7.86 (s, 1H), 7.72 (d, J =
9.06 Hz, 1H), 7.30−7.37 (m, 2H), 6.90 (br s, 1H), 6.70 (br s, 1H),
6.48 (br s, 1H), 3.91 (s, 3H), 3.68 (br s, 4H), 1.59−1.75 (m, 6H),
1.52 (s, 9H). 13C NMR (100 MHz, chloroform-d): δ 163.7, 159.8,
153.5, 139.3, 138.2, 135.5, 135.3, 124.6, 123.3, 122.6, 122.0, 119.2,
118.8, 115.3, 104.0, 80.3, 36.8, 28.4, 24.6. m/z: (ESI+) calcd for
C25H30N4O4S (M)
+, 482.2; found, 483.0 ([M] + H)+.
tert-Butyl(1-methyl-5-((2-(morpholine-4-carbonyl)benzofuran-5-
yl)carbamoyl)-1H-pyrrol-3-yl)carbamate (35). Obtained 0.038 g
(reaction yield: 40%) as a gray solid. 1H NMR (400 MHz,
chloroform-d): δ 8.01 (d, J = 2.01 Hz, 1H), 7.69 (s, 1H), 7.48 (d,
J = 8.81 Hz, 1H), 7.41 (dd, J = 8.94, 2.14 Hz, 1H), 7.31 (d, J = 0.76
Hz, 1H), 6.87 (s, 1H), 6.69 (s, 1H), 6.29 (br s, 1H), 3.93 (s, 3H),
3.89 (br s, 4H), 3.80 (br s, 4H), 1.52 (s, 9H). 13C NMR (100 MHz,
chloroform-d): δ 159.6, 159.5, 151.4, 149.5, 133.9, 127.2, 123.2,
121.9, 120.0, 118.6, 116.3, 113.4, 112.6, 111.9, 103.7, 80.2, 66.9, 36.7,
28.3. m/z: (ESI+) calcd for C24H28N4O6 (M)




tained 0.044 g (reaction yield: 48%) as a white solid. 1H NMR
(400 MHz, chloroform-d): δ 8.20 (d, J = 2.01 Hz, 1H), 7.92 (br s,
1H), 7.69 (d, J = 8.81 Hz, 1H), 7.37 (s, 1H), 7.31 (d, J = 8.81 Hz,
1H), 6.90 (br s, 1H), 6.70 (br s, 1H), 6.55 (br s, 1H), 3.89 (s, 3H),
3.55−370 (m, 8H), 1.51 (s, 9H). 13C NMR (100 MHz, chloroform-
d): δ 163.9, 159.7, 153.5, 139.2, 137.2, 135.6, 135.4, 125.4, 123.3,
122.7, 122.0, 119.4, 118.8, 115.3, 104.0, 80.4, 66.9, 36.8, 28.4. m/z:
(ESI+) calcd for C24H28N4O5S (M)
+, 484.1; found, 485.1 ([M] + H).
tert-Butyl(1-methyl-5-((2-(thiomorpholine-4-carbonyl)-
benzofuran-5-yl)carbamoyl)-1H-pyrrol-3-yl)carbamate (37). Ob-
tained 0.039 g (reaction yield: 41%) as a white solid. 1H NMR
(400 MHz, chloroform-d): δ 8.01 (d, J = 2.01 Hz, 1H), 7.67 (s, 1H),
7.48 (d, J = 8.81 Hz, 1H), 7.40 (dd, J = 8.81 Hz, 2.27 Hz, 1H), 6.87
(s, 1H), 6.69 (s, 1H), 6.27 (br s, 1H), 4.08 (br s, 4H), 3.93 (s, 3H),
2.73−2.80 (m, 4H), 1.52 (s, 9H). 13C NMR (100 MHz, chloroform-
d): δ 160.0, 159.7, 153.4, 151.5, 151.4, 149.6, 134.0, 127.4, 123.3,
120.1, 118.7, 113.5, 112.3, 112.1, 103.8, 80.4, 36.8, 28.4. m/z: (ESI+)
calcd for C24H28N4O5S (M)
+, 484.1; found, 485.1 ([M] + H)+.
tert-Butyl(1-methyl-5-((2-(thiomorpholine-4-carbonyl)benzo[b]-
thiophen-5-yl)carbamoyl)-1H-pyrrol-3-yl)carbamate (38). Ob-
tained 0.048 g (reaction yield: 50%) as a white solid. 1H NMR
(400 MHz, chloroform-d): δ 8.23 (s, 1H), 7.92 (s, 1H), 7.73 (d, J =
10.83 Hz, 1H), 7.33−7.40 (m, 2H), 6.87 (br s, 1H), 6.71 (br s, 1H),
6.45 (br s, 1H), 4.00 (br s, 4H), 3.91 (s, 3H), 2.71 (br s, 4H), 1.51 (s,
9H). 13C NMR (100 MHz, chloroform-d): δ 164.2, 159.8, 153.5,
139.2, 137.3, 135.6, 125.0, 123.3, 122.6, 122.0, 119.5, 118.9, 116.5,
115.4, 104.1, 80.4, 36.8, 35.6, 28.4, 27.9. m/z: (ESI+) calcd for
C24H28N4O4S2 (M)
+, 500.1; found, 501.2 ([M] + H)+.
Synthesis of Final Compounds 3−12. C8-boc-protected tails 29−
38 (1 equiv) were dissolved in MeOH (3 mL), and HCl 4 M in
dioxane (3 mL) was added to the solution that was left under a
magnetic stirrer for 2 h. TLC confirmed the deprotection of the
amine. The reaction mixture was evaporated under vacuum using a
rotary evaporator obtaining the formation of a light brown solid. PBD-
protected core 26 was dissolved in DMF (4 mL), and EDCI (2 equiv)
and DMAP (3 equiv) were added to the solution that was left under a
magnetic stirrer in a N2 atmosphere for 20 min. The desired,
deprotected, side chains were added to the reaction mixture that was
left under a magnetic stirrer overnight. TLC and LC−MS analysis
showed the formation of the protected PBD-C8 derivative. H2O (10
mL) was added to the reaction mixture to quench the reaction. The
aqueous phase was subsequently extracted with EtOAc (3 × 10 mL).
The collected organic phases were then washed with brine (10 mL),
NaHCO3-saturated aqueous solution (10 mL), and citric acid
aqueous solution 0.1 M (10 mL). The collected organic phase was
dried over MgSO4 and evaporated under vacuum using a rotary
evaporator. The obtained crude of the reaction was purified by
column chromatography (mobile phase: from DCM/acetone, 90/10,
v/v to DCM/acetone, 60/40/, v/v depending on the substrate), to
give protected PBD-conjugates. The obtained product (1 equiv) was
dissolved in DCM (4 mL) and tetrakis Pd (0.05 equiv), and
triphenylphosphine (0.25 equiv) and pyrrolidine (1.2 equiv) were
added to the solution. The reaction mixture was kept under a
magnetic stirrer for 20 min until TLC showed the completion of the
reaction. The solvent was evaporated under vacuum using a rotary
evaporator and subsequently under high vacuum to eliminate any
residue of pyrrolidine. The crude of the reaction was purified by
column chromatography (mobile phase: from DCM/acetone, 90/10,
v/v to DCM/acetone, 40/60/, v/v, depending on the substrate),




mide (3). Obtained 0.045 g (reaction yield: 64%) as a white solid. 1H
NMR (400 MHz, chloroform-d): δ 8.28 (s, 1H), 8.27 (s, 1H), 7.99
(d, J = 1.76 Hz, 1H), 7.64 (d, J = 4.53 Hz, 1H), 7.48 (s, 1H), 7.36−
7.46 (m, 2H), 7.20 (s, 1H), 7.15 (d, J = 1.76 Hz, 1H), 6.79 (s, 1H),
6.58 (d, J = 2.01 Hz, 1H), 3.97−4.08 (m, 2H), 3.87 (s, 3H), 3.84 (s,
3H), 3.76 (m, 1H), 3.66−3.72 (m, 1H), 3.51−3.57 (m, 1H), 3.32 (br
s, 3H), 3.13 (br s, 3H), 2.24−2.33 (m, 2H), 2.17−2.22 (m, 2H),
1.93−2.08 (m, 4H). 13C NMR (100 MHz, chloroform-d): δ 169.9,
164.7, 162.8, 160.9, 160.0, 151.4, 150.6, 149.7, 147.7, 140.62, 134.1,
127.2, 123.0, 121.7, 120.4, 120.3, 119.9, 113.7, 111.8, 111.6, 110.8,
104.1, 68.1, 56.1, 53.8, 46.7, 36.8, 32.9, 29.5, 29.3, 24.9, 24.2. HRMS






mide (4). Obtained 0.025 g (reaction yield: 56%) as a white solid. 1H
NMR (400 MHz, chloroform-d): δ 8.20 (s, 1H), 8.16 (s, 1H), 7.98
(d, J = 1.51 Hz, 1H), 7.65 (d, J = 4.28 Hz, 1H), 7.50 (s, 1H), 7.41−
7.45 (m, 2H), 7.22 (s, 1H), 7.15 (s, 1H), 6.80 (s, 1H), 6.57 (s, 1H),
4.07 (t, J = 5.67 Hz, 2H), 3.88 (s, 3H), 3.86 (s, 3H), 3.73−3.82 (m,
2H), 3.67−3.73 (m, 1H), 3.60 (br s, 4H), 2.45−2.53 (m, 2H), 2.25−
2.34 (m, 2H), 2.18−2.24 (m, 2H), 1.99−2.07 (m, 2H), 1.28 (br s,
6H). 13C NMR (100 MHz, chloroform-d): δ 169.9, 164.6, 160.3,
160.0, 151.4, 150.7, 150.3, 147.7, 140.6, 134.1, 127.4, 123.0, 121.6,
120.4, 120.2, 119.9, 113.7, 111.8, 111.7, 111.2, 110.9, 104.1, 69.5,
68.1, 56.1, 53.8, 46.7, 36.8, 31.8, 29.6, 29.3, 24.9, 24.2, 16.2. HRMS






mide (5). Obtained 0.020 g (reaction yield: 46%) as a white solid. 1H
NMR (400 MHz, chloroform-d): δ 8.18 (s, 1H), 8.13 (s, 1H), 7.98 (s,
1H), 7.65 (d, J = 4.28 Hz, 1H), 7.50 (s, 1H), 7.42−7.45 (m, 2H),
7.13−7.16 (m, 2H), 6.80 (s, 1H), 6.56 (d, J = 2.01 Hz, 1H), 4.06 (t, J
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= 6.17 Hz, 2H), 3.88 (s, 3H), 3.86 (s, 3H), 3.67−3.78 (m, 6H),
3.52−3.59 (m, 1H), 2.46−2.52 (m, 2H), 2.27−2.32 (m, 2H), 2.19−
2.24 (m, 2H), 2.00−2.07 (m, 2H), 1.62−1.71 (m, 6H). 13C NMR
(100 MHz, chloroform-d): δ 169.9, 164.6, 162.8, 160.0, 151.3, 150.7,
149.5, 147.7, 140.6, 134.1, 127.4, 123.0, 121.6, 120.4, 120.1, 119.8,
113.6, 111.8, 111.7, 111.1, 110.9, 104.0, 69.5, 56.1, 53.8, 46.7, 31.8,
29.3, 24.9, 24.6, 24.2. HRMS (ESI, m/z): calcd for C37H41N6O7 ([M]




mide (6). Obtained 0.030 g (reaction yield: 58%) as a white solid. 1H
NMR (400 MHz, chloroform-d): δ 8.04 (d, J = 1.51 Hz, 1H), 8.00 (s,
1H), 7.70 (s, 1H), 7.67 (d, J = 4.53 Hz, 1H), 7.54 (s, 1H), 7.46−7.50
(m, 2H), 7.30 (s, 1H), 7.12 (d, J = 1.76 Hz, 1H), 6.84 (s, 1H), 6.59
(d, J = 2.01 Hz, 1H), 4.15 (t, J = 5.92 Hz, 2H), 3.92 (s, 3H), 3.91 (s,
3H), 3.76−3.83 (m, 8H), 3.70−3.75 (m, 2H), 3.53−3.60 (m, 1H),
2.56 (t, J = 6.80 Hz, 2H), 2.23−2.34 (m, 4H), 2.00−2.10 (m, 2H).
13C NMR (100 MHz, chloroform-d): δ 169.9, 164.6, 162.8, 159.9,
151.5, 149.4, 140.7, 134.2, 127.4, 127.3, 123.1, 121.5, 120.4, 119.9,
119.5, 119.4, 118.8, 115.8, 113.9, 113.6, 112.7, 112.0, 111.8, 111.2,
104.1, 68.1, 67.0, 56.2, 53.8, 46.7, 36.8, 29.6, 25.0, 24.2. HRMS (ESI,
m/z): calcd for C36H39N6O8 ([M] + H)




boxamide (7). Obtained 0.030 g (reaction yield: 48%) as a light
yellow solid. 1H NMR (400 MHz, chloroform-d): δ 8.28 (s, 1H), 8.13
(s, 1H), 8.00 (d, J = 2.01 Hz, 1H), 7.64 (d, J = 4.28 Hz, 1H), 7.45−
7.49 (m, 2H), 7.39−7.43 (m, 1H), 7.21 (s, 1H), 7.11 (d, J = 1.76 Hz,
1H), 6.79 (s, 1H), 6.60 (d, J = 1.76 Hz, 1H), 3.99−4.09 (m, 6H),
3.87 (s, 3H), 3.84 (s, 3H), 3.74−3.81 (m, 1H), 3.66−3.71 (m, 1H),
3.49−3.57 (m, 1H), 2.70−2.77 (m, 4H), 2.46−2.52 (m, 2H), 2.25−
2.32 (m, 2H), 1.93−2.08 (m, 4H). 13C NMR (100 MHz, chloroform-
d): δ 169.9, 164.6, 162.8, 160.0, 159.9, 151.3, 150.6, 149.4, 147.8,
140.6, 134.3, 127.2, 123.0, 121.6, 120.5, 120.4, 119.8, 113.6, 112.3,
111.8, 104.2, 68.1, 56.1, 53.8, 46.7, 36.8, 32.9, 29.5, 29.3, 24.9, 24.2.






boxamide (8). Obtained 0.040 g (reaction yield: 67%) as a light
yellow solid. 1H NMR (400 MHz, DMSO-d6): δ 9.98 (s, 1H), 9.93 (s,
1H), 8.43 (d, J = 2.01 Hz, 1H), 7.91 (d, J = 8.81 Hz, 1H), 7.76−7.80
(m, 2H), 7.68 (dd, J = 8.81, 2.01 Hz, 1H), 7.33 (s, 1H), 7.24 (d, J =
1.76 Hz, 1H), 7.01 (d, J = 1.76 Hz, 1H), 6.83 (s, 1H), 4.09−4.16 (m,
1H), 4.00−4.07 (m, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.65−3.68 (m,
1H), 3.57−3.63 (m, 1H), 3.33−3.42 (m, 1H), 3.25 (br s, 3H), 3.06
(br s, 3H), 2.41−2.47 (m, 2H), 2.18−2.29 (m, 2H), 2.02−2.08 (m,
2H), 1.88−1.98 (m, 2H). 13C NMR (100 MHz, DMSO-d6): δ 168.9,
164.2, 163.3, 163.2, 159.8, 150.1, 146.9, 140.5, 139.2, 138.5, 136.6,
133.9, 126.0, 122.5, 122.2, 122.1, 119.9, 119.8, 118.9, 115.3, 111.2,
104.8, 68.5, 55.8, 53.4, 46.3, 36.2, 32.1, 29.6, 28.8, 24.4. HRMS (ESI,






mide (9). Obtained 0.031 g (reaction yield: 62%) as a yellow solid. 1H
NMR (400 MHz, DMSO-d6): δ 9.94 (s, 1H), 9.98 (s, 1H), 8.45 (s,
1H), 7.91 (d, J = 8.78 Hz, 1H), 7.75 (d, J = 4.40 Hz, 1H), 7.57−7.70
(m, 2H), 7.33 (s, 1H), 7.24 (s, 1H), 7.02 (s, 1H), 6.83 (s, 1H), 4.09−
4.20 (m, 1H), 3.96−4.09 (m, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.63−
3.71 (m, 2H), 3.55−3.63 (m, 1H), 3.49 (br s, 4H), 2.40−2.46 (m,
2H), 2.16−2.26 (m, 2H), 1.99−2.05 (m, 2H), 1.90−1.95 (m, 2H),
1.19 (br s, 6H). 13C NMR (100 MHz, DMSO-d6): δ 168.6, 162.8,
159.8, 158.3, 154.6, 151.7, 150.0, 147.9, 143.3, 140.8, 139.2, 138.5,
136.6, 134.9, 133.7, 129.9, 127.0, 124.4, 123.4, 122.5, 122.2, 122.0,
119.8, 118.9, 116.4, 115.4, 110.6, 68.5, 55.8, 36.3, 30.7, 29.6, 24.4,






boxamide (10). Obtained 0.030 g (reaction yield: 69%) as a yellow
solid. 1H NMR (400 MHz, chloroform-d): δ 8.26 (d, J = 1.76 Hz,
1H), 8.10 (s, 1H), 7.99 (s, 1H), 7.75 (d, J = 8.56 Hz, 1H), 7.66 (d, J =
4.53 Hz, 1H), 7.52 (s, 1H), 7.42 (dd, J = 8.69, 2.14 Hz, 1H), 7.38 (s,
1H), 7.15 (d, J = 1.51 Hz, 1H), 6.82 (s, 1H), 6.56 (d, J = 1.76 Hz,
1H), 4.09 (t, J = 6.17 Hz, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 3.77−3.84
(m, 2H), 3.68 (br s, 5H), 2.48−2.55 (m, 2H), 2.27−2.34 (m, 2H),
2.20−2.27 (m, 2H), 2.00−2.09 (m, 2H), 1.55−1.69 (m, 6H). HRMS






boxamide (11). Obtained 0.030 g (reaction yield: 48%) as a yellow
solid. 1H NMR (400 MHz, chloroform-d): δ 8.29 (s, 1H), 8.10 (s,
1H), 7.82 (s, 1H), 7.77 (d, J = 8.56 Hz, 1H), 7.67 (d, J = 4.28 Hz,
1H), 7.53 (s, 1H), 7.47 (d, J = 9.06 Hz, 1H), 7.42 (s, 1H), 7.13 (s,
1H), 6.83 (s, 1H), 6.60 (s, 1H), 4.12 (t, J = 5.79 Hz, 2H), 3.91 (s,
3H), 3.90 (br s, 4H), 3.79 (br s, 9H), 3.54−3.62 (m, 1H), 2.50−2.58
(m, 2H), 2.28−2.32 (m, 2H), 2.21−2.27 (m, 2H), 2.00−2.10 (m,
2H). 13C NMR (100 MHz, chloroform-d): δ 170.0, 164.6, 163.9,
162.8, 153.6, 150.6, 147.7, 140.7, 137.1, 132.7, 130.7, 125.4, 123.0,
122.7, 121.5, 120.6, 120.0, 119.7, 115.5, 111.8, 111.1, 110.5, 68.1,
66.9, 56.2, 53.5, 46.7, 36.8, 33.1, 25.0, 24.2. HRMS (ESI, m/z): calcd
for C36H39N6O7S ([M] + H)




carboxamide (12). Obtained 0.024 g (reaction yield: 57%) as a
yellow solid. 1H NMR (400 MHz, chloroform-d): δ 8.29 (s, 1H), 8.11
(s, 1H), 7.83 (s, 1H), 7.76 (d, J = 8.56 Hz, 1H), 7.67 (d, J = 4.28 Hz,
1H), 7.53 (s, 1H), 7.44−7.49 (m, 1H), 7.40 (s, 1H), 7.13 (s, 1H),
6.84 (s, 1H), 6.60 (s, 1H), 4.08−4.15 (m, 2H), 4.01 (br s, 4H), 3.91
(s, 3H), 3.90 (s, 3H), 3.73−3.82 (m, 1H), 3.68−3.74 (m, 1H), 3.52−
3.61 (m, 1H), 2.72 (br s, 4H), 2.49−2.57 (m, 2H), 2.27−2.35 (m,
2H), 2.19−2.26 (m, 2H), 1.98−2.09 (m, 2H). 13C NMR (100 MHz,
chloroform-d): δ 170.0, 164.6, 164.1, 162.7, 150.6, 147.7, 140.6,
139.2, 137.3, 135.7, 135.4, 125.0, 123.1, 122.6, 121.5, 120.6, 120.0,
119.7, 116.2, 115.5, 111.8, 111.1, 104.2, 68.1, 56.2, 53.8, 46.7, 36.8,
33.1, 29.6, 29.3, 25.0, 24.2. HRMS (ESI, m/z): calcd for
C36H39N6O6S2 ([M] + H)
+, 715.2367; found, 715.2367.
Synthesis of Methyl 4-(4-((tert-Butoxycarbonyl)amino)phenyl)-
1-methyl-1H-pyrrole-2-carboxylate (39). Commercially available
methyl 4-bromo-1-methyl-1H-pyrrole-2-carboxylate (1.0 g, 4 mmol,
1 equiv) was dissolved in a mixture of ACN (40 mL) and H2O (36
mL), and commercially available (4-((tert-butoxycarbonyl)amino)-
phenyl)boronic acid (1.1 equiv) and K2CO3 (3 equiv) were added to
the solution that was transferred to a microwave vial. The reaction
mixture was degassed using N2. Tetrakis Pd (0.05 equiv) was added to
the reaction mixture that was then heated under microwave radiation
at 100 °C for 6 min. TLC and LC−MS analysis showed the formation
of the product, but the reaction did not go to completion. The
reaction mixture was filtered under vacuum through a path of Celite
and washed with AcOEt. The filtrate was evaporated under vacuum
using a rotary evaporator. The obtained solid residue was purified by
column chromatography on silica gel (mobile phase: DCM/AcOEt,
80/20, v/v) giving pure 39 (0.635 g, reaction yield: 42%) as an amber
oil. 1H NMR (400 MHz, chloroform-d): δ 7.47−7.52 (m, 1H), 7.41−
7.44 (m, 2H), 7.32−7.38 (m, 2H), 7.17 (d, J = 2.01 Hz, 1H), 7.04 (d,
J = 2.27 Hz, 1H), 3.96 (s, 3H), 3.85 (s, 3H), 1.53 (s, 9H). 13C NMR
(101 MHz, chloroform-d): δ 161.9, 153.1, 136.8, 135.7, 129.4, 127.2,
126.2, 123.5, 119.2, 114.7, 80.5, 51.1, 37.2, 28.4. m/z: (ESI+) calcd for
C18H22N2O4 (M)
+, 330.1; found, 331.0 ([M] + H)+.
Synthesis of Methyl 4-(4-(4-((tert-Butoxycarbonyl)amino)-1-
methyl-1H-pyrrole-2-carboxamido)phenyl)-1-methyl-1H-pyrrole-2-
carboxylate (40). Compound 39 (1.2 equiv) was dissolved in MeOH
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(7 mL), and HCl 4 M in dioxane (7 mL) was added to the solution
that was left under a magnetic stirrer for 2 h until TLC showed the
completion of the reaction. The reaction mixture was then evaporated
under vacuum using a rotary evaporator.
Commercially available 4-((tert-butoxycarbonyl)amino)-1-methyl-
1H-pyrrole-2-carboxylic acid (0.659 g, 2.7 mmol, 1 equiv) was
dissolved in DMF (7 mL), and EDCI (2.4 equiv) and DMAP (3
equiv) were added to the solution that was left to stir in a N2
atmosphere for 30 min. The deprotected compound 39 was added to
the reaction mixture and left to stir overnight at room temperature in
a N2 atmosphere. The reaction did not go to completion and was
quenched by the addition of H2O (10 mL). The aqueous phase was
then extracted with AcOEt (3 × 10 mL). The organic phase was
sequentially washed with citric acid 0.1 M aqueous solution (10 mL),
saturated NaHCO3 aqueous solution (10 mL), and brine (10 mL).
The collected organic phase was dried over MgSO4 and evaporated
under vacuum using a rotary evaporator. The crude of the reaction
was purified by column chromatography on silica gel (mobile phase:
DCM/AcOEt, 60/40, v/v), giving pure compound 40 (0.621 g,
reaction yield: 50%) as a white solid. 1H NMR (400 MHz,
chloroform-d): δ 7.64 (s, 1H), 7.53 (d, J = 8.81 Hz, 2H), 7.45 (d,
J = 8.81 Hz, 2H), 7.19 (d, J = 2.01 Hz, 1H), 7.06 (d, J = 2.27 Hz, 1H),
6.85 (br s, 1H), 6.64 (br s, 1H), 6.31 (br s, 1H), 3.96 (s, 3H), 3.91 (s,
3H), 3.85 (s, 3H), 1.52 (s, 9H). 13C NMR (101 MHz, chloroform-d):
δ 161.7, 159.7, 153.4, 140.5, 136.3, 134.4, 130.4, 126.2, 123.6, 123.0,
122.0, 118.9, 114.8, 112.4, 103.8, 80.3, 50.9, 37.0, 36.7, 28.2. m/z:
(ESI+) calcd for C24H28N4O5 (M)
+, 452.2; found, 453.1 ([M] + H)+.
Synthesis of MPB Side Chains 41 to 43. Starting from
intermediate 40, the same procedure used for the synthesis and




Obtained 0.060 g (reaction yield: 50%) as light yellow solid. 1H
NMR (400 MHz, chloroform-d): δ 7.67 (s, 1H), 7.45−7.54 (m, 2H),
7.40 (d, J = 8.56 Hz, 2H), 6.93 (d, J = 1.76 Hz, 1H), 6.87 (br s, 1H),
6.62 (br s, 1H), 6.54 (d, J = 1.76 Hz, 1H), 6.47 (br s, 1H), 3.90 (s,
3H), 3.77 (s, 3H), 3.65−3.73 (m, 4H), 1.71 (br s, 2H), 1.60−1.66
(m, 4H), 1.51 (s, 9H). 13C NMR (101 MHz, chloroform-d): δ 162.7,
159.5, 153.4, 135.8, 130.9, 126.6, 125.4, 123.5, 122.8, 122.28, 121.9,
120.3, 118.5, 109.2, 103.7, 80.2, 47.9, 36.7, 35.7, 28.3, 25.7, 24.7. m/z:
(ESI+) calcd for C28H35N5O4 (M)
+, 505.2; found, 506.2 ([M] + H)+.
tert-Butyl(1-methyl-5-((4-(1-methyl-5-(morpholine-4-carbonyl)-
1H-pyrrol-3-yl)phenyl)carbamoyl)-1H-pyrrol-3-yl)carbamate (42).
Obtained 0.087 g, (reaction yield: 72%) as a yellow-orange solid.
1H NMR (400 MHz, chloroform-d): δ 7.70 (br s, 1H), 7.50 (d, J =
7.05 Hz, 2H), 7.36 (d, J = 7.55 Hz, 2H), 6.97 (br s, 1H), 6.85 (br s,
1H), 6.65 (br s, 1H), 6.55 (br s, 1H), 6.46 (br s, 1H), 3.90 (br s, 3H),
3.80 (br s, 7H), 3.74 (br s, 4H), 1.51 (br s, 9H). 13C NMR (101
MHz, chloroform-d): δ 163.1, 159.5, 153.8, 140.9, 136.2, 130.7, 125.4,
123.5, 122.9, 122.1, 122.0, 120.3, 118.5, 110.2, 103.8, 80.3, 67.1, 38.6,
36.5, 35.7, 28.4. m/z: (ESI+) calcd for C27H33N5O5 (M)
+, 507.2;
found, 508.1 ([M] + H)+.
tert-Butyl(1-methyl-5-((4-(1-methyl-5-(thiomorpholine-4-car-
bonyl)-1H-pyrrol-3-yl)phenyl)carbamoyl)-1H-pyrrol-3-yl)-
carbamate (43). Obtained 0.040 g (reaction yield: 86%) as a yellow
oil. 1H NMR (400 MHz, chloroform-d): δ 7.64 (br s, 1H), 7.52 (d, J
= 8.06 Hz, 2H), 7.36 (d, J = 8.06 Hz, 2H), 6.97 (s, 1H), 6.85 (br s,
1H), 6.64 (br s, 1H), 6.54 (s, 1H), 6.38 (br s, 1H), 4.04 (br s, 4H),
3.91 (s, 3H), 3.78 (s, 3H), 2.71 (br s, 4H), 1.51 (br s, 9H). 13C NMR
(101 MHz, chloroform-d): δ 163.1, 159.5, 153.4, 135.9, 130.6, 125.8,
125.5, 123.5, 123.0, 122.9, 121.8, 120.3, 118.6, 109.6, 103.7, 80.4,
36.7, 35.8, 28.3, 27.9. m/z: (ESI+) calcd for C27H33N5O4S (M)
+,
523.2; found, 524.1 ([M] + H)+.
Synthesis of Bromo-Pyrrole Intermediates 44 and 45. Starting
from commercially available N-methyl bromo-pyrrole methyl ester,
the same procedure used for the synthesis and purification of
compound 21 (after basic hydrolysis of the methyl ester) was applied
to give intermediates 44−45.
The crude of reaction was purified by column chromatography on
silica gel (mobile phase: DCM/AcOEt, 80/20, v/v), giving pure
compounds 44 and 45.
4-Bromo-N,N,1-trimethyl-1H-pyrrole-2-carboxamide (44). Ob-
tained 0.420 g (reaction yield: 74%) as a light yellow solid. 1H
NMR (400 MHz, chloroform-d): δ 6.67 (s, 1H), 6.34 (s, 1H), 3.74 (s,
3H), 3.12 (br s, 6H). 13C NMR (101 MHz, chloroform-d): δ 163.1,
126.2, 125.2, 114.9, 94.0, 35.8. m/z: (ESI+) calcd for C8H11BrN2O
(M)+, 230.0; found, 230.9 ([M] + H)+.
4-Bromo-N,N-diethyl-1-methyl-1H-pyrrole-2-carboxamide (45).
Obtained 0.484 g (reaction yield: 77%) as a light brown solid. 1H
NMR (400 MHz, chloroform-d): δ 6.65 (d, J = 1.76 Hz, 1H), 6.28 (d,
J = 1.76 Hz, 1H), 3.68 (s, 3H), 3.49 (q, J = 7.22 Hz, 4H), 1.19 (t, J =
7.18 Hz, 6H). 13C NMR (101 MHz, chloroform-d): δ 162.7, 126.7,
124.9, 112.6, 94.2, 42.5, 35.9, 11.2. m/z: (ESI+) calcd for
C10H15BrN2O (M)
+, 258.0; found, 260.9 ([M] + H)+.
Synthesis of MPB Derivatives 46 and 47. Starting from
intermediates 44−45, the same procedure used for the synthesis
and purification of compound 39 was applied to give intermediates
46−47.
tert-Butyl(4-(5-(dimethylcarbamoyl)-1-methyl-1H-pyrrol-3-yl)-
phenyl)carbamate (46). Obtained 0.360 g (reaction yield: 61%) as
an orange-brown solid. 1H NMR (400 MHz, chloroform-d): δ 7.36−
7.41 (m, 2H), 7.30−7.36 (m, 2H), 6.93 (d, J = 2.01 Hz, 1H), 6.60 (d,
J = 2.01 Hz, 1H), 6.52 (s, 1H), 3.81 (s, 3H), 3.17 (s, 6H), 1.53 (s,
9H). 13C NMR (101 MHz, chloroform-d): δ 164.1, 152.8, 136.2,
130.0, 126.2, 125.2, 122.8, 122.7, 119.1, 110.4, 80.5, 36.2, 28.4. m/z:
(ESI+) calcd for C19H25N3O3 (M)
+, 343.1; found, 344.0 ([M] + H)+.
tert-Butyl(4-(5-(diethylcarbamoyl)-1-methyl-1H-pyrrol-3-yl)-
phenyl)carbamate (47). Obtained 0.313 g (46%) ad a light yellow
solid. 1H NMR (400 MHz, chloroform-d): δ 7.72−7.76 (m, 2H),
7.66−7.72 (m, 2H), 7.27 (s, 1H), 7.03 (s, 1H), 6.91 (d, J = 2.01 Hz,
1H), 4.12 (s, 3H), 3.93 (q, J = 7.05 Hz, 4H), 1.89 (s, 9H), 1.61 (t, J =
7.18 Hz, 6H). 13C NMR (101 MHz, chloroform-d): δ 163.7, 152.7,
135.8, 129.9, 127.0, 125.7, 123.1, 121.6, 118.7, 108.4, 80.2, 35.5, 28.4,
13.7. m/z: (ESI+) calcd for C21H29N3O3 (M)
+, 371.22; found, 372.1
([M] + H)+.
Synthesis of MPB Tails 48−49. Starting from intermediates 46−
47, the same procedure used for the synthesis and purification of
compound 40 was applied to give intermediates 48−49.
tert-Butyl(5-((4-(5-(dimethylcarbamoyl)-1-methyl-1H-pyrrol-3-
yl)phenyl)carbamoyl)-1-methyl-1H-pyrrol-3-yl)carbamate (48).
Obtained 0.185 g (reaction yield: 95%) as a brown solid. 1H NMR
(400 MHz, chloroform-d): δ 7.65 (s, 1H), 7.50 (d, J = 8.56 Hz, 2H),
7.38 (d, J = 8.56 Hz, 2H), 6.94 (d, J = 1.76 Hz, 1H), 6.86 (s, 1H),
6.62 (s, 2H), 6.43 (br s, 1H), 3.90 (s, 3H), 3.80 (s, 3H), 3.18 (br s,
6H), 1.51 (s, 9H). 13C NMR (101 MHz, chloroform-d): δ 163.9,
159.7, 153.6, 136.0, 130.8, 126.4, 125.5, 124.1, 123.5, 122.6, 121.9,
120.6, 118.6, 110.4, 103.5, 80.4, 37.0, 35.8, 28.2. m/z: (ESI+) calcd for
C25H31N5O4 (M)
+, 465.2; found, 466.1 ([M] + H)+.
tert-Butyl(5-((4-(5-(diethylcarbamoyl)-1-methyl-1H-pyrrol-3-yl)-
phenyl)carbamoyl)-1-methyl-1H-pyrrol-3-yl)carbamate (49). Ob-
tained 0.090 g (reaction yield: 53%) as a light yellow solid. 1H NMR
(400 MHz, chloroform-d): δ 7.64 (s, 1H), 7.50 (d, J = 8.56 Hz, 2H),
7.39 (d, J = 8.56 Hz, 2H), 6.93 (d, J = 2.01 Hz, 1H), 6.86 (s, 1H),
6.61 (s, 1H), 6.57 (d, J = 2.01 Hz, 1H), 6.47 (br s, 1H), 3.90 (s, 3H),
3.76 (s, 3H), 3.58 (q, J = 6.88 Hz, 4H), 1.51 (s, 9H), 1.22−1.27 (m,
6H). 13C NMR (101 MHz, chloroform-d): δ 163.3, 159.8, 153.8,
136.0, 131.4, 127.1, 124.9, 124.0, 122.7, 122.0, 121.9, 120.2, 118.7,
108.0, 103.8, 80.3, 37.3, 35.4, 28.3, 14.0. m/z: (ESI+) calcd for
C27H35N5O4 (M)
+, 493.2; found, 494.1 ([M] + H)+.
Synthesis of Final Compounds 13−17. Starting from the
appropriate intermediates, the same procedure used for the synthesis





pyrrole-2-carboxamide (13). Obtained 0.044 g (reaction yield: 70%)
as a light yellow solid. 1H NMR (400 MHz, DMSO-d6): δ 9.90 (s,
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1H), 9.76 (s, 1H), 7.77 (d, J = 4.53 Hz, 1H), 7.62−7.69 (d, J = 8.81
Hz, 2H), 7.44−7.50 (d, J = 8.56 Hz, 2H), 7.33 (s, 1H), 7.30 (d, J =
1.76 Hz, 1H), 7.20 (d, J = 1.76 Hz, 1H), 6.95 (d, J = 1.76 Hz, 1H),
6.82 (s, 1H), 6.75 (d, J = 1.76 Hz, 1H), 4.08−4.17 (m, 1H), 3.99−
4.08 (m, 1H), 3.82 (s, 6H), 3.68 (s, 4H), 3.55−3.63 (m, 1H), 3.37−
3.41 (m, 1H), 3.07 (br s, 6H), 2.44 (t, J = 7.43 Hz, 2H), 2.15−2.33
(m, 2H), 2.00−2.07 (m, 2H), 1.92 (d, J = 5.54 Hz, 2H). 13C NMR
(101 MHz, DMSO-d6): δ 168.6, 164.4, 163.3, 162.4, 159.3, 150.4,
146.7, 140.7, 139.0, 136.9, 129.6, 126.2, 124.1, 122.7, 122.6, 121.8,
120.5, 115.8, 114.4, 119.8, 111.2, 110.1, 109.2, 104.5, 67.3, 54.8, 53.7,
46.2, 36.0, 31.8, 28.5, 24.7, 23.4. HRMS (ESI, m/z): calcd for
C37H41N7O6 ([M] + H)




2-carboxamide (14). Obtained 0.029 g (reaction yield: 64%) as a
white solid. 1H NMR (400 MHz, chloroform-d): δ 8.22 (br s, 1H),
7.86 (br s, 1H), 7.66 (d, J = 4.53 Hz, 1H), 7.51 (s, 1H), 7.44−7.49 (d,
J = 8.56 Hz, 2H), 7.33−7.41 (d, J = 8.81 Hz, 2H), 7.17 (d, J = 1.76
Hz, 1H), 6.94 (d, J = 1.51 Hz, 1H), 6.82 (s, 1H), 6.59 (d, J = 2.01 Hz,
1H), 6.35 (d, J = 1.51 Hz, 1H), 4.10 (t, J = 6.17 Hz, 2H), 3.89 (s,
6H), 3.76−3.80 (m, 1H), 3.74 (s, 3H), 3.68−3.72 (m, 1H), 3.53−
3.62 (m, 5H), 2.49−2.53 (m, 2H), 2.26−2.33 (m, 2H), 2.23 (t, J =
6.67 Hz, 2H), 1.98−2.09 (m, 2H), 1.25 (t, J = 7.05 Hz, 6H). 13C
NMR (101 MHz, chloroform-d): δ 170.0, 165.0, 163.7, 162.8, 160.1,
150.7, 147.9, 140.6, 136.2, 130.7, 127.4, 125.5, 122.9, 121.5, 119.6,
112.1, 110.8, 108.4, 104.0, 68.2, 56.4, 53.7, 47.0, 36.9, 35.8, 33.1, 29.9,
25.2, 24.3, 18.0. HRMS (ESI, m/z): calcd for C39H45N7O6 ([M] +




role-2-carboxamide (15). Obtained 0.021 g (reaction yield: 81%) as
a light brown solid. 1H NMR (400 MHz, chloroform-d): δ 8.06 (s,
1H), 7.84 (s, 1H), 7.66 (d, J = 4.53 Hz, 1H), 7.52 (s, 1H), 7.46−7.51
(d, J = 8.31 Hz, 2H), 7.34−7.43 (d, J = 8.56 Hz, 2H), 7.13−7.19 (m,
1H), 6.95 (d, J = 1.76 Hz, 1H), 6.83 (s, 1H), 6.56 (d, J = 1.51 Hz,
1H), 6.40 (d, J = 1.51 Hz, 1H), 4.11 (t, J = 5.92 Hz, 2H), 3.90 (s,
6H), 3.78−3.84 (m, 1H), 3.76 (s, 3H), 3.69−3.73 (m, 4H), 3.54−
3.63 (m, 2H), 2.50−2.57 (m, 2H), 2.27−2.35 (m, 2H), 2.20−2.26
(m, 2H), 1.98−2.09 (m, 2H), 1.66−1.75 (m, 6H). 13C NMR (101
MHz, chloroform-d): δ 169.9, 164.6, 162.8, 160.3, 159.7, 150.7, 147.8,
140.7, 136.1, 130.7, 130.5, 126.8, 125.4, 123.3, 123.0, 122.4, 121.6,
120.7, 120.5, 119.8, 111.9, 111.1, 109.1, 103.5, 68.1, 56.4, 53.7, 46.6,
36.9, 35.6, 32.8, 29.7, 25.0, 24.7, 24.3. HRMS (ESI, m/z): calcd for
C40H45N7O6 ([M] + H)




pyrrole-2-carboxamide (16). Obtained 0.032 g (reaction yield: 50%)
as a light yellow solid. 1H NMR (400 MHz, DMSO-d6): δ 9.91 (s,
1H), 9.78 (s, 1H), 7.78 (br s, 1H), 7.61−7.71 (m, 2H), 7.44−7.52
(m, J = 7.81 Hz, 2H), 7.34 (br s, 2H), 7.21 (s, 1H), 6.96 (s, 1H), 6.83
(s, 1H), 6.71 (s, 1H), 4.10−4.16 (m, 1H), 4.00−4.08 (m, 1H), 3.83
(s, 6H), 3.70 (s, 3H), 3.64 (br s, 10H), 3.56−3.60 (m, 1H), 2.44 (t, J
= 7.05 Hz, 2H), 2.15−2.25 (m, 2H), 1.99−2.15 (m, 2H), 1.88−1.98
(m, 2H). 13C NMR (101 MHz, DMSO-d6): δ 168.9, 164.3, 163.4,
162.0, 159.5, 150.3, 146.9, 140.7, 137.0, 129.6, 125.5, 124.5, 123.2,
123.0, 122.7, 122.0, 121.9, 120.3, 11.3, 110.o, 109.0, 104.6, 67.8, 66.3,
55.4, 54.8, 46.5, 36.4, 31.8, 29.7, 28.7, 24.8, 23.7. HRMS (ESI, m/z):
calcd for C39H43N7O7 ([M] + H)




1H-pyrrole-2-carboxamide (17). Obtained 0.077 g (reaction yield:
96%) as a light brown solid. 1H NMR (400 MHz, chloroform-d): δ
7.98 (s, 1H), 7.92 (s, 1H), 7.66 (d, J = 4.53 Hz, 1H), 7.53 (d, J = 8.56
Hz, 2H), 7.51 (s, 1H), 7.38 (d, J = 8.56 Hz, 2H), 7.14 (d, J = 1.76 Hz,
1H), 6.97 (d, J = 1.76 Hz, 1H), 6.82 (s, 1H), 6.55 (d, J = 1.76 Hz,
1H), 6.45 (d, J = 2.01 Hz, 1H), 4.09 (t, J = 6.42 Hz, 2H), 4.03 (dd, J
= 7.05, 2.77 Hz, 4H), 3.89 (s, 3H), 3.88 (s, 3H), 3.78−3.83 (m, 1H),
3.77 (s, 3H), 3.68−3.74 (m, 1H), 3.51−3.61 (m, 1H), 2.67−2.73 (m,
4H), 2.48−2.54 (m, 2H), 2.27−2.35 (m, 2H), 2.20−2.26 (m, 2H),
2.00−2.08 (m, 2H). 13C NMR (101 MHz, chloroform-d): δ 169.8,
164.6, 163.1, 162.7, 159.6, 150.6, 147.7, 140.6, 136.1, 130.4, 125.8,
125.4, 123.3, 123.0, 122.9, 121.5, 120.5, 120.4, 119.8, 111.6, 110.9,
109.5, 103.7, 68.1, 64.5, 56.1, 53.7, 46.7, 36.7, 35.8, 32.9, 29.5, 29.2,
27.9, 24.9, 24.2. HRMS (ESI, m/z): calcd for C39H43N7O7 ([M] +
H)+, 738.3068; found, 738.3075.
Bacterial Strains. Bacterial strains used in this study are listed in
Tables 1 and 2. All isolates were cultured in tryptic soy broth (TSB)
and on TSA plates at 37 °C. All chemicals were sourced from Sigma-
Aldrich unless otherwise stated. Strains from the P. aeruginosa PAO125
and K. pneumoniae MKP103 transposon26 mutant libraries were
obtained from the University of Washington, Genome services, WA,
USA.
Susceptibility Testing. The MIC was determined using the
microdilution broth method.27 Compounds were initially dissolved in
dimethyl sulfoxide (DMSO) prior to dilution in broth. Equivalent
concentrations of solvent had no effect on bacterial growth. The MIC
was defined as the lowest concentration of compound which resulted
in no visible growth at an optical density of 600 nm. Experiments were
performed in triplicate.
Time-Kill Curve Analysis. Three independent repeats were
performed for each strain with each compound. Fresh TSB media (10
mL) was inoculated with ∼1 × 107 cfu/mL of the test organism.
Bacteria were challenged at 4× MIC for each compound and
incubated at 37 °C in a rotary shaker at 200 rpm. One hundred
microliter aliquots were taken at 0, 1, 2, 4, 6, and 24 h post
inoculation and serial dilutions performed in sterile phosphate-
buffered saline. Total viable counts were determined by the Miles−
Misra dilutions method. The compound is considered bactericidal if
the inoculum was reduced >3 log10 cfu/mL and bacteriostatic if
inoculum was decreased by 0−3 log10 cfu/mL.
Efflux and Influx Assays. An adapted microdilution broth
method was performed to evaluate the efflux potential of the
compounds. In this assay, 50 μL/well of EPI at 4× final concentration
and 50 μL/well of the test organism at 2 × 105 cfu/mL were added to
wells containing 100 μL/well of a dilution series of compound. CCCP
was added at a final concentration of 10 mg/L, and phenylalanine−
arginine β-naphthylamide PAβN was added at 25 mg/L. TSB media
was supplemented with MgSO4 (40 μM) to prevent the
permeabilization of the outer membrane of Gram-negative bacteria
by PAβN.18 A decrease in MIC of the compound of at least fourfold
was defined as significant for efflux activity.28
The influx assay was performed exactly as described for the efflux
assay, with the addition of PMBN at a final concentration of 30 mg/L.
Transposon mutants in efflux pump genes in P. aeruginosa strain
PAO1 were generated as described previously29 and provided via
http://www.gs.washington.edu/labs/manoil/libraryindex.html.
Gyrase Inhibition Assay. The effect of the antimicrobial agents
on the gyrase activity was assessed using the S. aureus and E. coli
gyrase supercoiling gel-based assays obtained from Inspiralis
(Norwich, UK).30 Methods were conducted as per the manufacturer’s
instructions.
Whole Genome Sequence Analysis and Transposon
Mutants. NCTC 13368 isolates resistant to compound 7 were
analyzed to identify the site of mutations. Isolates were passaged 10
times in the absence of selection and checked to confirm that the
resistance phenotype was maintained. DNA was isolated and the
genome was sequenced by PHE-GSDU on an Illumina (HiSeq 2500)
as previously described.31 Potential individual mutations were
identified using Galaxy.32
Cell Culture and MTT Assay. WI-38 cell line was obtained from
the American Type Culture Collection. The cells were grown in
normal conditions in an incubator at 37 °C in a humidified
atmosphere containing 5% CO2. The appropriate medium [Eagle’s
minimum essential medium (MEM) or MEM, Gibco] supplemented
with fetal bovine serum (10%, v/v, Sigma-Aldrich) was used for
culturing the cells. The viability assay was conducted in a 96-well
plate, and the plates were left under continuous incubation with the
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drug for 24 h. The media was removed, the MTT reagent was added,
and finally, the absorbance of the formazan crystals was read using a
plate reader (Envision Plate Reader, PerkinElmer). The values of
absorbance obtained were normalized with the blank and then used
for the determination of the % of viability compared to the control.
For single-point toxicity screening, the number of repeats (n) was
equal to 6, and the result is reported as average values.
FRET-Based DNA Melting Assay. The modified, fluorophore-
tagged hairpin oligonucleotides were purchased from Eurogentec. The
assay was carried out using a previously published procedure7 with 5:1
ligand oligonucleotide ratio. The working solution of 400 nM was
made in FRET buffer (50 mM potassium cacodylate, pH 7.4) and
annealed by heating the working solution at 90 °C for 6 min followed
by cooling to room temperature and storage at this temperature for 5
h before the assay. The compound and oligonucleotide were
combined in a 1:1 ratio (25 μL of each) in a 96-well plate and
were heated in the range of 30−100 °C after 3 h incubation at 25 °C.
The fluorescence readings (excitation 490 nm, emission 520 nm)
were taken at fixed intervals of 0.5 °C, over the cited range. The data
obtained by the instrument were processed through normalization of
the curve using Origin 7.0 (OriginLab Corp., USA). The DNA
melting temperature values were then determined using a preset script
that determined the values as the point of inflection of the first
derivative of the curve. Each experiment was conducted in triplicate,
and the values reported are the ΔTm average along with the standard
deviation of the mean.
Mutation Frequency. Mutation frequencies were determined
following the method of Evans and Titlow (1998). Briefly, 100 μL of
bacterial culture, grown to an OD600 of approximately 0.5−0.6 was
used to inoculate the surface of TSB agar containing compounds at a
range of concentrations above and below the MIC. The plates were
then incubated at 37 °C and the plates assessed for the presence of
colonies following 48 h incubation. Miles−Misra was also performed
on drug free TSA plates to determine the exact number of cfu/mL in
the initial culture. Mutation frequencies were then calculated by
dividing the number of colonies on plates containing the specific
agents by the total number of colony-forming units (cfu) that were
plated.
Reporter Strain Assays. Strains from the E. coli K12 MG1655
promoter library created by Zaslaver et al.20 were purchased from
Dharmacon (GE Life Sciences). Strains were maintained on 25 mg/L
kanamycin TSA plates and cultured in M9 media supplemented with
1% glucose, 0.2% casamino acids, 0.5 mg/L thiamine, 100 μM CaCl2,
2 mM MgSO4, and 25 mg/L kanamycin.
21 Twofold serial dilutions of
compounds were made up in DMSO to 50× the required
concentration, with a previously determined inhibitory concentration
in the middle of the series. The dilution series (2 μL) was added per
well, with 2 μL of DMSO in “untreated” wells, and then, 98 μL of
overnight culture back diluted to an OD600 of 0.2 was added to each
well. Strain U66 or U139, containing the promoterless plasmids
pUA66 or pUA139, respectively, was included for every compound
tested as a negative control. Plates were incubated at 37 °C with 200
rpm in a CLARIOstar microplate reader (BMG Labtech).
Fluorescence (RFU) and cell growth (OD600) were measured every
30 min for 20 h. Fluorescence data were normalized by cell density
(RFU/OD600) at 9 h, where fluorescence became stable, and at the
highest concentration of compound for which there was growth. Fold
induction of the promoter was calculated by dividing the fluorescence
of the treated sample by fluorescence of the untreated sample.
Molecular Docking of the Compounds to Gyrase A.
AutoDock SMINA was used for molecular docking of compounds 7
and 8 to the minimized crystal structure of gyrase A from S. aureus
(PDB ID 2XCT) and cryo EM structure of gyrase A from E. coli
(PDB ID 6RKS) for finding the best binding pocket by exploring all
probable binding cavities in the enzyme. All of the parameters were
kept in their default values. Then, GOLD molecular docking was used
for molecular docking of the compounds into the SMINA-located
binding site for performing flexible molecular docking and
determining more precise and evaluated energies and scores.33,34
Based on the fitness function score and ligand binding position, the
best-docked pose for each compound was selected.
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